Unresectable Head and Neck Squamous Cell Carcinoma Clinical Trials

12 clinical trials for Unresectable Head and Neck Squamous Cell Carcinoma across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma — RECRUITING · PHASE1
• A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 — RECRUITING · PHASE2
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors — RECRUITING · PHASE1
• Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery — ACTIVE_NOT_RECRUITING · PHASE1
• Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial — NOT_YET_RECRUITING · PHASE2
• Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma — ACTIVE_NOT_RECRUITING · PHASE3
• Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer — COMPLETED · PHASE1
• Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma — COMPLETED · PHASE1
• Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer — WITHDRAWN · PHASE2
• Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat — TERMINATED · PHASE2

Refine this search